Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
Identifieur interne : 000268 ( Pmc/Curation ); précédent : 000267; suivant : 000269Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
Auteurs : Min Z. Levine [États-Unis] ; Crystal Holiday [États-Unis] ; Stacie Jefferson [États-Unis] ; F. Liaini Gross [États-Unis] ; Feng Liu [États-Unis] ; Sheng Li [États-Unis] ; Damien Friel [Belgique] ; Philippe Boutet [Belgique] ; Bruce L. Innis [États-Unis] ; Corey P. Mallett [États-Unis] ; Terrence M. Tumpey [États-Unis] ; James Stevens [États-Unis] ; Jacqueline M. Katz [États-Unis]Source :
- NPJ Vaccines [ 2059-0105 ] ; 2019.
Abstract
Highly pathogenic avian influenza (HPAI) A(H5Nx) viruses continue to pose a pandemic threat. US national vaccine stockpiles are a cornerstone of the influenza pandemic preparedness plans. However, continual genetic and antigenic divergence of A(H5Nx) viruses requires the development of effective vaccination strategies using stockpiled vaccines and adjuvants for pandemic preparedness. Human sera collected from healthy adults who received either homologous (2 doses of a AS03A-adjuvanted A/turkey/Turkey/1/2005, A/Turkey), or heterologous (primed with AS03A-adjuvanted A/Indonesia/5/2005, A/Indo, followed by A/Turkey boost) prime-boost vaccination regimens were analyzed by hemagglutination inhibition and microneutralization assays against 8 wild-type HPAI A(H5Nx) viruses from 6 genetic clades. Molecular, structural and antigenic features of the A(H5Nx) viruses that could influence the cross-clade antibody responses were also explored. Compared with homologous prime-boost vaccinations, priming with a clade 2.1.3.2 antigen (A/Indo) followed by one booster dose of a clade 2.2.1 antigen (A/Turkey) administered 18 months apart did not compromise the antibody responses to the booster vaccine (A/Turkey), it also broadened the cross-clade antibody responses to several antigenically drifted variants from 6 heterologous clades, including an antigenically distant A(H5N8) virus (A/gyrfalcon/Washington/410886/2014, clade 2.3.4.4) that caused recent outbreaks in US poultry. The magnitude and breadth of the cross-clade antibody responses against emerging HPAI A(H5Nx) viruses are associated with genetic, structural and antigenic differences from the vaccine viruses and enhanced by the inclusion of an adjuvant. Heterologous prime-boost vaccination with AS03A adjuvanted vaccine offers a vaccination strategy to use existing stockpiled vaccines for pandemic preparedness against new emerging HPAI A(H5Nx) viruses.
Url:
DOI: 10.1038/s41541-019-0114-8
PubMed: 31149353
PubMed Central: 6541649
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000268
Links to Exploration step
PMC:6541649Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost</title><author><name sortKey="Levine, Min Z" sort="Levine, Min Z" uniqKey="Levine M" first="Min Z." last="Levine">Min Z. Levine</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Holiday, Crystal" sort="Holiday, Crystal" uniqKey="Holiday C" first="Crystal" last="Holiday">Crystal Holiday</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Jefferson, Stacie" sort="Jefferson, Stacie" uniqKey="Jefferson S" first="Stacie" last="Jefferson">Stacie Jefferson</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Gross, F Liaini" sort="Gross, F Liaini" uniqKey="Gross F" first="F. Liaini" last="Gross">F. Liaini Gross</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000000095689541</institution-id><institution-id institution-id-type="GRID">grid.27873.39</institution-id><institution>Battelle Memorial Institute,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Liu, Feng" sort="Liu, Feng" uniqKey="Liu F" first="Feng" last="Liu">Feng Liu</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Li, Sheng" sort="Li, Sheng" uniqKey="Li S" first="Sheng" last="Li">Sheng Li</name><affiliation wicri:level="2"><nlm:aff id="Aff5"><institution-wrap><institution-id institution-id-type="GRID">grid.476870.a</institution-id><institution>Biomedical Advanced Research and Development Authority,</institution></institution-wrap>Washington, DC USA</nlm:aff><country>États-Unis</country><placeName><region type="state">District de Columbia</region></placeName><wicri:cityArea>Washington</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff6">Present Address: Sciogen, Los Altos, CA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Present Address: Sciogen, Los Altos</wicri:cityArea></affiliation></author><author><name sortKey="Friel, Damien" sort="Friel, Damien" uniqKey="Friel D" first="Damien" last="Friel">Damien Friel</name><affiliation wicri:level="1"><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.425090.a</institution-id><institution>GSK Vaccines,</institution></institution-wrap>Wavre, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Wavre</wicri:regionArea></affiliation></author><author><name sortKey="Boutet, Philippe" sort="Boutet, Philippe" uniqKey="Boutet P" first="Philippe" last="Boutet">Philippe Boutet</name><affiliation wicri:level="1"><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.425090.a</institution-id><institution>GSK Vaccines,</institution></institution-wrap>Wavre, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Wavre</wicri:regionArea></affiliation></author><author><name sortKey="Innis, Bruce L" sort="Innis, Bruce L" uniqKey="Innis B" first="Bruce L." last="Innis">Bruce L. Innis</name><affiliation wicri:level="2"><nlm:aff id="Aff4">GSK Vaccines, Rockville, MD USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>GSK Vaccines, Rockville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff7"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0423 0663</institution-id><institution-id institution-id-type="GRID">grid.416809.2</institution-id><institution>Present Address: PATH,</institution></institution-wrap>Washington, DC USA</nlm:aff><country>États-Unis</country><placeName><region type="state">District de Columbia</region></placeName><wicri:cityArea>Washington</wicri:cityArea></affiliation></author><author><name sortKey="Mallett, Corey P" sort="Mallett, Corey P" uniqKey="Mallett C" first="Corey P." last="Mallett">Corey P. Mallett</name><affiliation wicri:level="2"><nlm:aff id="Aff4">GSK Vaccines, Rockville, MD USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>GSK Vaccines, Rockville</wicri:cityArea></affiliation></author><author><name sortKey="Tumpey, Terrence M" sort="Tumpey, Terrence M" uniqKey="Tumpey T" first="Terrence M." last="Tumpey">Terrence M. Tumpey</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Stevens, James" sort="Stevens, James" uniqKey="Stevens J" first="James" last="Stevens">James Stevens</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Katz, Jacqueline M" sort="Katz, Jacqueline M" uniqKey="Katz J" first="Jacqueline M." last="Katz">Jacqueline M. Katz</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31149353</idno><idno type="pmc">6541649</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541649</idno><idno type="RBID">PMC:6541649</idno><idno type="doi">10.1038/s41541-019-0114-8</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000268</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000268</idno><idno type="wicri:Area/Pmc/Curation">000268</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000268</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost</title><author><name sortKey="Levine, Min Z" sort="Levine, Min Z" uniqKey="Levine M" first="Min Z." last="Levine">Min Z. Levine</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Holiday, Crystal" sort="Holiday, Crystal" uniqKey="Holiday C" first="Crystal" last="Holiday">Crystal Holiday</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Jefferson, Stacie" sort="Jefferson, Stacie" uniqKey="Jefferson S" first="Stacie" last="Jefferson">Stacie Jefferson</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Gross, F Liaini" sort="Gross, F Liaini" uniqKey="Gross F" first="F. Liaini" last="Gross">F. Liaini Gross</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000000095689541</institution-id><institution-id institution-id-type="GRID">grid.27873.39</institution-id><institution>Battelle Memorial Institute,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Liu, Feng" sort="Liu, Feng" uniqKey="Liu F" first="Feng" last="Liu">Feng Liu</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Li, Sheng" sort="Li, Sheng" uniqKey="Li S" first="Sheng" last="Li">Sheng Li</name><affiliation wicri:level="2"><nlm:aff id="Aff5"><institution-wrap><institution-id institution-id-type="GRID">grid.476870.a</institution-id><institution>Biomedical Advanced Research and Development Authority,</institution></institution-wrap>Washington, DC USA</nlm:aff><country>États-Unis</country><placeName><region type="state">District de Columbia</region></placeName><wicri:cityArea>Washington</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff6">Present Address: Sciogen, Los Altos, CA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Present Address: Sciogen, Los Altos</wicri:cityArea></affiliation></author><author><name sortKey="Friel, Damien" sort="Friel, Damien" uniqKey="Friel D" first="Damien" last="Friel">Damien Friel</name><affiliation wicri:level="1"><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.425090.a</institution-id><institution>GSK Vaccines,</institution></institution-wrap>Wavre, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Wavre</wicri:regionArea></affiliation></author><author><name sortKey="Boutet, Philippe" sort="Boutet, Philippe" uniqKey="Boutet P" first="Philippe" last="Boutet">Philippe Boutet</name><affiliation wicri:level="1"><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.425090.a</institution-id><institution>GSK Vaccines,</institution></institution-wrap>Wavre, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Wavre</wicri:regionArea></affiliation></author><author><name sortKey="Innis, Bruce L" sort="Innis, Bruce L" uniqKey="Innis B" first="Bruce L." last="Innis">Bruce L. Innis</name><affiliation wicri:level="2"><nlm:aff id="Aff4">GSK Vaccines, Rockville, MD USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>GSK Vaccines, Rockville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff7"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0423 0663</institution-id><institution-id institution-id-type="GRID">grid.416809.2</institution-id><institution>Present Address: PATH,</institution></institution-wrap>Washington, DC USA</nlm:aff><country>États-Unis</country><placeName><region type="state">District de Columbia</region></placeName><wicri:cityArea>Washington</wicri:cityArea></affiliation></author><author><name sortKey="Mallett, Corey P" sort="Mallett, Corey P" uniqKey="Mallett C" first="Corey P." last="Mallett">Corey P. Mallett</name><affiliation wicri:level="2"><nlm:aff id="Aff4">GSK Vaccines, Rockville, MD USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>GSK Vaccines, Rockville</wicri:cityArea></affiliation></author><author><name sortKey="Tumpey, Terrence M" sort="Tumpey, Terrence M" uniqKey="Tumpey T" first="Terrence M." last="Tumpey">Terrence M. Tumpey</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Stevens, James" sort="Stevens, James" uniqKey="Stevens J" first="James" last="Stevens">James Stevens</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author><author><name sortKey="Katz, Jacqueline M" sort="Katz, Jacqueline M" uniqKey="Katz J" first="Jacqueline M." last="Katz">Jacqueline M. Katz</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName><wicri:cityArea>Atlanta</wicri:cityArea></affiliation></author></analytic><series><title level="j">NPJ Vaccines</title><idno type="eISSN">2059-0105</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="Par1">Highly pathogenic avian influenza (HPAI) A(H5Nx) viruses continue to pose a pandemic threat. US national vaccine stockpiles are a cornerstone of the influenza pandemic preparedness plans. However, continual genetic and antigenic divergence of A(H5Nx) viruses requires the development of effective vaccination strategies using stockpiled vaccines and adjuvants for pandemic preparedness. Human sera collected from healthy adults who received either homologous (2 doses of a AS03<sub>A</sub>-adjuvanted A/turkey/Turkey/1/2005, A/Turkey), or heterologous (primed with AS03<sub>A</sub>-adjuvanted A/Indonesia/5/2005, A/Indo, followed by A/Turkey boost) prime-boost vaccination regimens were analyzed by hemagglutination inhibition and microneutralization assays against 8 wild-type HPAI A(H5Nx) viruses from 6 genetic clades. Molecular, structural and antigenic features of the A(H5Nx) viruses that could influence the cross-clade antibody responses were also explored. Compared with homologous prime-boost vaccinations, priming with a clade 2.1.3.2 antigen (A/Indo) followed by one booster dose of a clade 2.2.1 antigen (A/Turkey) administered 18 months apart did not compromise the antibody responses to the booster vaccine (A/Turkey), it also broadened the cross-clade antibody responses to several antigenically drifted variants from 6 heterologous clades, including an antigenically distant A(H5N8) virus (A/gyrfalcon/Washington/410886/2014, clade 2.3.4.4) that caused recent outbreaks in US poultry. The magnitude and breadth of the cross-clade antibody responses against emerging HPAI A(H5Nx) viruses are associated with genetic, structural and antigenic differences from the vaccine viruses and enhanced by the inclusion of an adjuvant. Heterologous prime-boost vaccination with AS03<sub>A</sub> adjuvanted vaccine offers a vaccination strategy to use existing stockpiled vaccines for pandemic preparedness against new emerging HPAI A(H5Nx) viruses.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Cox, Nj" uniqKey="Cox N">NJ Cox</name></author><author><name sortKey="Trock, Sc" uniqKey="Trock S">SC Trock</name></author><author><name sortKey="Burke, Sa" uniqKey="Burke S">SA Burke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, Gj" uniqKey="Smith G">GJ Smith</name></author><author><name sortKey="Donis, Ro" uniqKey="Donis R">RO Donis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Baz, M" uniqKey="Baz M">M Baz</name></author><author><name sortKey="Luke, Cj" uniqKey="Luke C">CJ Luke</name></author><author><name sortKey="Cheng, X" uniqKey="Cheng X">X Cheng</name></author><author><name sortKey="Jin, H" uniqKey="Jin H">H Jin</name></author><author><name sortKey="Subbarao, K" uniqKey="Subbarao K">K Subbarao</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Uyeki, Tm" uniqKey="Uyeki T">TM Uyeki</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Treanor, Jj" uniqKey="Treanor J">JJ Treanor</name></author><author><name sortKey="Campbell, Jd" uniqKey="Campbell J">JD Campbell</name></author><author><name sortKey="Zangwill, Km" uniqKey="Zangwill K">KM Zangwill</name></author><author><name sortKey="Rowe, T" uniqKey="Rowe T">T Rowe</name></author><author><name sortKey="Wolff, M" uniqKey="Wolff M">M Wolff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leroux Roels, I" uniqKey="Leroux Roels I">I Leroux-Roels</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jennings, Lc" uniqKey="Jennings L">LC Jennings</name></author><author><name sortKey="Monto, As" uniqKey="Monto A">AS Monto</name></author><author><name sortKey="Chan, Pk" uniqKey="Chan P">PK Chan</name></author><author><name sortKey="Szucs, Td" uniqKey="Szucs T">TD Szucs</name></author><author><name sortKey="Nicholson, Kg" uniqKey="Nicholson K">KG Nicholson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levine, Mz" uniqKey="Levine M">MZ Levine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jhung, Ma" uniqKey="Jhung M">MA Jhung</name></author><author><name sortKey="Nelson, Di" uniqKey="Nelson D">DI Nelson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Langley, Jm" uniqKey="Langley J">JM Langley</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Yang, H" uniqKey="Yang H">H Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wiley, Dc" uniqKey="Wiley D">DC Wiley</name></author><author><name sortKey="Wilson, Ia" uniqKey="Wilson I">IA Wilson</name></author><author><name sortKey="Skehel, Jj" uniqKey="Skehel J">JJ Skehel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stray, Sj" uniqKey="Stray S">SJ Stray</name></author><author><name sortKey="Pittman, Lb" uniqKey="Pittman L">LB Pittman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pulit Penaloza, Ja" uniqKey="Pulit Penaloza J">JA Pulit-Penaloza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ip, Hs" uniqKey="Ip H">HS Ip</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khurana, S" uniqKey="Khurana S">S Khurana</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peeters, B" uniqKey="Peeters B">B Peeters</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koel, Bf" uniqKey="Koel B">BF Koel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duvvuri, Vr" uniqKey="Duvvuri V">VR Duvvuri</name></author><author><name sortKey="Duvvuri, B" uniqKey="Duvvuri B">B Duvvuri</name></author><author><name sortKey="Cuff, Wr" uniqKey="Cuff W">WR Cuff</name></author><author><name sortKey="Wu, Ge" uniqKey="Wu G">GE Wu</name></author><author><name sortKey="Wu, J" uniqKey="Wu J">J Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Banzhoff, A" uniqKey="Banzhoff A">A Banzhoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garcon, N" uniqKey="Garcon N">N Garcon</name></author><author><name sortKey="Vaughn, Dw" uniqKey="Vaughn D">DW Vaughn</name></author><author><name sortKey="Didierlaurent, Am" uniqKey="Didierlaurent A">AM Didierlaurent</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moris, P" uniqKey="Moris P">P Moris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leroux Roels, I" uniqKey="Leroux Roels I">I Leroux-Roels</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nolan, T" uniqKey="Nolan T">T Nolan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tarlinton, D" uniqKey="Tarlinton D">D Tarlinton</name></author><author><name sortKey="Good Jacobson, K" uniqKey="Good Jacobson K">K Good-Jacobson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, Jt" uniqKey="Wu J">JT Wu</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Waterhouse, A" uniqKey="Waterhouse A">A Waterhouse</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stevens, J" uniqKey="Stevens J">J Stevens</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Vaccines</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Vaccines</journal-id><journal-title-group><journal-title>NPJ Vaccines</journal-title></journal-title-group><issn pub-type="epub">2059-0105</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31149353</article-id><article-id pub-id-type="pmc">6541649</article-id><article-id pub-id-type="publisher-id">114</article-id><article-id pub-id-type="doi">10.1038/s41541-019-0114-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3197-1649</contrib-id><name><surname>Levine</surname><given-names>Min Z.</given-names></name><address><phone>+404-639-3504</phone><email>Mlevine@cdc.gov</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Holiday</surname><given-names>Crystal</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jefferson</surname><given-names>Stacie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gross</surname><given-names>F. Liaini</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Feng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Sheng</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Friel</surname><given-names>Damien</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Boutet</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Innis</surname><given-names>Bruce L.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Mallett</surname><given-names>Corey P.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tumpey</surname><given-names>Terrence M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stevens</surname><given-names>James</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Katz</surname><given-names>Jacqueline M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution>Influenza Division, Centers for Disease Control and Prevention,</institution></institution-wrap>Atlanta, GA USA</aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000095689541</institution-id><institution-id institution-id-type="GRID">grid.27873.39</institution-id><institution>Battelle Memorial Institute,</institution></institution-wrap>Atlanta, GA USA</aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.425090.a</institution-id><institution>GSK Vaccines,</institution></institution-wrap>Wavre, Belgium</aff><aff id="Aff4"><label>4</label>GSK Vaccines, Rockville, MD USA</aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.476870.a</institution-id><institution>Biomedical Advanced Research and Development Authority,</institution></institution-wrap>Washington, DC USA</aff><aff id="Aff6"><label>6</label>Present Address: Sciogen, Los Altos, CA USA</aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0423 0663</institution-id><institution-id institution-id-type="GRID">grid.416809.2</institution-id><institution>Present Address: PATH,</institution></institution-wrap>Washington, DC USA</aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>4</volume><elocation-id>22</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>3</day><month>5</month><year>2019</year></date></history><permissions><copyright-statement>© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Highly pathogenic avian influenza (HPAI) A(H5Nx) viruses continue to pose a pandemic threat. US national vaccine stockpiles are a cornerstone of the influenza pandemic preparedness plans. However, continual genetic and antigenic divergence of A(H5Nx) viruses requires the development of effective vaccination strategies using stockpiled vaccines and adjuvants for pandemic preparedness. Human sera collected from healthy adults who received either homologous (2 doses of a AS03<sub>A</sub>-adjuvanted A/turkey/Turkey/1/2005, A/Turkey), or heterologous (primed with AS03<sub>A</sub>-adjuvanted A/Indonesia/5/2005, A/Indo, followed by A/Turkey boost) prime-boost vaccination regimens were analyzed by hemagglutination inhibition and microneutralization assays against 8 wild-type HPAI A(H5Nx) viruses from 6 genetic clades. Molecular, structural and antigenic features of the A(H5Nx) viruses that could influence the cross-clade antibody responses were also explored. Compared with homologous prime-boost vaccinations, priming with a clade 2.1.3.2 antigen (A/Indo) followed by one booster dose of a clade 2.2.1 antigen (A/Turkey) administered 18 months apart did not compromise the antibody responses to the booster vaccine (A/Turkey), it also broadened the cross-clade antibody responses to several antigenically drifted variants from 6 heterologous clades, including an antigenically distant A(H5N8) virus (A/gyrfalcon/Washington/410886/2014, clade 2.3.4.4) that caused recent outbreaks in US poultry. The magnitude and breadth of the cross-clade antibody responses against emerging HPAI A(H5Nx) viruses are associated with genetic, structural and antigenic differences from the vaccine viruses and enhanced by the inclusion of an adjuvant. Heterologous prime-boost vaccination with AS03<sub>A</sub> adjuvanted vaccine offers a vaccination strategy to use existing stockpiled vaccines for pandemic preparedness against new emerging HPAI A(H5Nx) viruses.</p></abstract><abstract id="Abs2" abstract-type="LongSummary"><title>Influenza vaccines: Heterologous prime-boost broadens cross-clade responses</title><p id="Par2">Influenza viruses are highly variable and display continuous antigenic drift, limiting the effectiveness of vaccine stockpiles and demanding new strategies to enhance vaccine effectiveness. Here, Min Levine from the Centers for Disease Control and Prevention and colleagues report a heterologous prime-boost A(H5N1) vaccination regimen that induced a broader cross-clade response when compared with homologous vaccination. In the study, adults primed with a clade 2.1.3.2 antigen (A/Indo) followed by one booster dose of a clade 2.2.1 antigen (A/Turkey) presented with enhanced hemagglutinin inhibition and neutralizing antibody titers to eight A(H5Nx) viruses without limiting the antibody response to the A/Turkey booster vaccine. Given that no individual H5 clade has led to protection against all H5 viruses, heterologous vaccination strategies that provide cross-clade reactivity may lead to more effective protection against influenza virus infection.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Immunology</kwd><kwd>Diseases</kwd><kwd>Medical research</kwd><kwd>Influenza virus</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000030</institution-id><institution>U.S. Department of Health & Human Services | Centers for Disease Control and Prevention (CDC)</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100012399</institution-id><institution>U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (BARDA)</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000268 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000268 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:6541649
|texte= Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:31149353" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |